Publication:
Self-rated health predicts adverse events during beta-blocker treatment: The CIBIS-ELD randomised trial analysis

dc.contributor.authorLainscak, Mitja (9739432000)
dc.contributor.authorFarkas, Jerneja (25225081600)
dc.contributor.authorInkrot, Simone (35784615000)
dc.contributor.authorGelbrich, Götz (14119833600)
dc.contributor.authorNeskovic, Aleksandar N. (35597744900)
dc.contributor.authorRau, Thomas (57214509568)
dc.contributor.authorTahirovic, Elvis (24339336300)
dc.contributor.authorTöpper, Agnieszka (38863078500)
dc.contributor.authorApostolovic, Svetlana (13610076800)
dc.contributor.authorHaverkamp, Wilhelm (7005423154)
dc.contributor.authorHerrmann-Lingen, Christoph (6603417225)
dc.contributor.authorAnker, Stefan D. (56223993400)
dc.contributor.authorDüngen, Hans-Dirk (16024171900)
dc.date.accessioned2025-06-12T21:17:29Z
dc.date.available2025-06-12T21:17:29Z
dc.date.issued2013
dc.description.abstractBackground: Self-rated health (SRH) predicts outcome in patients with heart failure. Beta-blockers are known to improve health-related quality of life and reduce mortality in such patients. We aimed to evaluate the relation between SRH and adverse events during titration of beta-blockers in elderly patients with heart failure. Methods: The cardiac insufficiency bisoprolol study in the elderly (CIBIS-ELD) is a multicentre, double-blind trial, in which 883 patients aged ≥ 65 years with chronic heart failure (73 ± 6 years, 38% women, left ventricular ejection fraction [LVEF] 42% ± 14%) were randomised to bisoprolol or carvedilol. SRH was assessed at baseline and after 12 weeks, using a 5-grade descriptive scale: excellent, very good, good, fair, and poor. Results: Median SRH at baseline and follow-up was good, but more patients reported fair/poor SRH at baseline (36% vs. 30%, p = 0.012). Women, beta-blocker-naïve patients, patients in NYHA class III/IV and those with PHQ-9 score ≥ 12 were more likely to report fair/poor baseline SRH (p < 0.001 for all). During follow-up, SRH improved in 34% of patients and worsened in 8% (p < 0.001). Adverse events were experienced by 64% patients and 38% experienced > 1 adverse event or serious adverse event, with higher prevalence in lower SRH categories. In a multivariate logistic regression model, SRH, age, distance achieved on the 6-min walk test and LVEF > 45% predicted adverse events (p < 0.05 for all). Conclusions: SRH is an independent predictor of adverse events during titration of beta-blockers and correlates with the proportion and number of adverse events per patient. © 2011 Elsevier Ireland Ltd. All rights reserved.
dc.identifier.urihttps://doi.org/10.1016/j.ijcard.2011.05.037
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84873083872&doi=10.1016%2fj.ijcard.2011.05.037&partnerID=40&md5=d77687fa0d2e5948def6529b5cbb072a
dc.identifier.urihttps://remedy.med.bg.ac.rs/handle/123456789/9223
dc.subjectBisoprolol
dc.subjectCarvedilol
dc.subjectElderly
dc.subjectHeart failure
dc.subjectSelf-rated health
dc.titleSelf-rated health predicts adverse events during beta-blocker treatment: The CIBIS-ELD randomised trial analysis
dspace.entity.typePublication

Files